Abstract：Objective: To investigate the effect of bone bridge formation on the mobility function of patients with ankylosing spondylitis (AS), so as to provide a basis for the development of early intervention measures. Methods: Ninety-two patients with AS who had developed bone bridges in the Department of Rheumatology from March 2020 to October 2024 were selected as the study group, and 94 patients with AS who did not have bone bridges and anterior vertebral bone sclerosis during the same period were selected as the control group. With the help of the measurement of the occipital wall distance and the finger-ground distance, the Schober test and related indexes, the mSASSS score was performed by imaging examination, and the Bath Ankylosing Spondylitis Functional Index (BASFI) score was measured for the patients. The influence of mSASSS on BASFI was analyzed through regression analysis, and the influence of the formation of the bone bridges on the mobility was then analyzed. Results: The occipital-wall distance and finger-ground distance of the patients in the study group were significantly higher than those in the control group, but the results of the Schober test were significantly lower than those in the control group (P<0.001). The mSASSS and BASFI scores of the study group were significantly higher than those of the control group (P<0.05), and the regression analysis showed that there was a significant positive correlation between mSASSS and BASFI (β=0.43, 95%CI 0.27-0.59, p<0.001), indicating that the formation of bone bridges greatly reduces vertebral body mobility in patients with AS, and has a significantly unfavourable effects. Conclusion: Bone bridge formation affects the mobility of AS patients, and early identification and timely intervention are clinically important to optimize the prognosis of patients.
梁志强, 王铭浩, 陈艳红, 赵蕾, 姜凤云, 岳静静. 强直性脊柱炎患者骨桥形成对活动功能的影响[J]. 河北医学, 2025, 31(7): 1186-1190.
LIANG Zhiqiang, WANG Minghao, et al. Effect of bone Bridge Formation on Mobility in Patients with Ankylosing Spondylitis. HeBei Med, 2025, 31(7): 1186-1190.
[1] Mauro D,Thomas R,Guggino G,et al.Ankylosing spondylitis: an autoimmune or autoinflammatory disease[J].Nature Reviews Rheumatology,2021(2):1-18. [2] Lee Y H,Song G G.Janus kinase inhibitors for treating active ankylosing spondylitis: a meta-analysis of randomized controlled trials[J]. Z Rheumatol,2022,81(1):71-76. [3] Roncada E,Brambilla V R,Filitto B F,et al.Atopic dermatitis as a paradoxical effect of secukinumab for the treatment of psoriasis[J]. Case ReP Dermatol,2021,13(2):336-339. [4] Michelena X,LoPez-Medina C,Marzo-Ortega H.Non-radiographic versus radiographic axSPA: what's in a name[J]. Rheumatology,2020,59(4):18-24. [5] Lian J B,Stein G S,Van Wijnen A J,et al.MicroRNA control of bone formation and homeostasis[J]. Nature Reviews Endocrinology,2012,8(4):212-227. [6] Chen CW,Wei JC,Gu J,Yu D.Editorial: advances in pathogenesis, etiology, and therapies for ankylosing spondylitis[J]. Front Immunol,2021,23(12):822582. [7] Sieper J,APPel H,Jurgen Braun,et al.Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes[J].Arthritis & Rheumatism,2010,58(3):649-656. [8] Sun W T,He Y H,Dong M M,et al.The comparative safety of biological treatment in patients with axial spondylarthritis: a meta-analysis of randomized controlled trials with placebo[J]. EuroPean Review for Medical & Pharmacological Sciences,2020,24(19):9824-9836. [9] Kwon S R,Lim M J,Suh C H,et al.DickkoPf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy[J].Rheumatology International,2012,32(8):2523-2527. [10] Hallstrom M,Klingberg E,Deminger A,et al.Physical function and sex differences in radiographic axial spondyloarthritis: a cross-sectional analysis on bath ankylosing spondylitis functional index[J]. Arthritis Res Ther,2023,25(1):182. [11] Debusschere K,Cambre I,Gracey E,et al.Born to run:the paradox of biomechanical force in spondy loarthritis from an evolutionary perspective[J].Best Pract Res Clin Rheumatol,2017,31(6):887-894. [12] Herrero-Beaumont G,Perez-Baos S,San Chez-Pernaute O,et al.Targeting chronic innate inflammatory pathways,the main road to prevention of osteoarthritis progression[J].Biochem Pharma col,2019,165(27):24-32. [13] Nelson D A,KaPlan R M,Kurina L M,et al.Incidence of ankylosing spondylitis among male and female united states army personnel[J]. Arthritis Care & Research,2023,75(2):332-339. [14] Nam S W,Sung Y K,Kim D,et al.The usefulness of trabecular bone score in patients with ankylosing spondylitis[J]. The Korean Journal of Internal Medicine,2021,36(5):1211-1220. [15] 万伟,李璇,张兰玲,等.肿瘤坏死因子α抑制剂治疗强直性脊柱炎合并骨质疏松症5年随访研究[J].海军军医大学学报,2024,45(12):1495-1501.
2025, Vol. 31 
冀公网安备13080202000786号